
A meta-analysis comparing docetaxel plus capecitabine (TX) and docetaxel plus epirubicin (TE) in HER2-negative breast cancer found no significant differences in survival or response rates. However, TX was linked to lower neutropenia risk but a higher incidence of hand-foot syndrome. These findings highlight the need for individualized treatment selection based on toxicity profiles.
Like
Save
Share